Literature DB >> 23657524

Screening of reducing agents for the PEGylation of recombinant human IL-10.

Alexandre Ambrogelly1, Collette Cutler, Brittany Paporello.   

Abstract

PEGylation is a technology commonly used to enhance the bioavailability of therapeutic proteins in patients. Reductive alkylation of a protein amino terminal alpha amine in the presence of a polyethylene glycol (PEG) chain derivatized with propionaldehyde and a reducing agent, typically sodium cyanoborohydride, is one of the technologies available to achieve quantitative and site specific PEGylation. While cyanoborohydride has proven to be a robust and efficient reagent for this type of reaction, it generates aqueous cyanide as a reaction by-product (and its corollary, the very volatile hydrogen cyanide). We report here the screening of reducing agents such as dimethylamine borane, trimethylamine borane, triethylamine borane, tert-butylamine borane, morpholine borane, pyridine borane, 2-picoline borane, and 5-ethyl-2-methyl-pyridine borane as alternatives to cyanoborohydride for the PEGylation of recombinant human IL-10. The results of our study show that pyridine borane and 2-picoline borane promote rhIL-10 PEGylation at levels comparable to those observed with cyanoborohydride.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23657524     DOI: 10.1007/s10930-013-9491-4

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  5 in total

1.  2-picoline-borane: a non-toxic reducing agent for oligosaccharide labeling by reductive amination.

Authors:  L Renee Ruhaak; Evelyne Steenvoorden; Carolien A M Koeleman; André M Deelder; Manfred Wuhrer
Journal:  Proteomics       Date:  2010-06       Impact factor: 3.984

Review 2.  State of the art in PEGylation: the great versatility achieved after forty years of research.

Authors:  Gianfranco Pasut; Francesco M Veronese
Journal:  J Control Release       Date:  2011-11-07       Impact factor: 9.776

3.  Pyridine borane as a reducing agent for proteins.

Authors:  W S Wong; D T Osuga; R E Feeney
Journal:  Anal Biochem       Date:  1984-05-15       Impact factor: 3.365

Review 4.  The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

Authors:  G Molineux
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 5.  Mono-N-terminal poly(ethylene glycol)-protein conjugates.

Authors:  Olaf Kinstler; Graham Molineux; Michael Treuheit; David Ladd; Colin Gegg
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

  5 in total
  1 in total

1.  Raman Spectroscopic and Quantum Chemical Investigation of the Pyridine-Borane Complex and the Effects of Dative Bonding on the Normal Modes of Pyridine.

Authors:  Ethan C Lambert; Benjamin W Stratton; Nathan I Hammer
Journal:  ACS Omega       Date:  2022-04-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.